H.C. Arentsen

548 citations
25 papers · 290 · h-index 10

Impact in

  • Urology top 10%
    • Urological Disorders and Treatments
    • Urinary Bladder and Prostate Research
  • Surgery
    • Bladder and Urothelial Cancer Treatments
    • Urinary and Genital Oncology Studies

Papers in

  • Surgery 22
    • Bladder and Urothelial Cancer Treatments 21
    • Urinary and Genital Oncology Studies 8
    • Esophageal Cancer Research and Treatment 2
  • Biotechnology 6
    • Cancer Research and Treatments 6
Co-authors
J. Alfred Witjes (11 shared papers)Egbert Oosterwijk (12 shared papers)Theo M. de Reijke (3 shared papers)Kees Hendricksen (3 shared papers)Erik B. Cornel (2 shared papers)Dirk Zaak (1 shared paper)Didier Jacqmin (1 shared paper)Hugh Mostafid (1 shared paper)
Journals
The Journal of Urology (5 papers)Urologic Oncology Seminars and Original Investigations (3 papers)Annals of Oncology (2 papers)World Journal of Urology (2 papers)Hematology/Oncology Clinics of North America (1 paper)
Partner nations
NetherlandsBelgiumItaly

In The Last Decade

H.C. Arentsen

22 papers receiving 281 citations

Peers

H.C. Arentsen
Comparison fields: 5 of 62
  • Urology 62
  • Surgery 215
  • Immunology 33
  • Cancer Research 23
  • Toxicology 4
Replace Ch. Bouffioux with:
Ch. Bouffioux Belgium
Roberto Carando Italy
Wenxi Tan China
BERND POSCH Austria
F. Johannes P. van Valenberg Netherlands
Weidong Xu China
J.P. Burgués Spain
Xiaofeng Yang China
U.O. Nseyo United States
Myron Roberts United States
H.C. Arentsen relative to Ch. Bouffioux Belgium Ch. Bouffioux's profile →
Citations per field
00.5×2×4×6×8×9×
Ch. Bouffioux · 1×
Citations per year

Countries citing papers authored by H.C. Arentsen

Since Specialization
Citations

This map shows the geographic impact of H.C. Arentsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.C. Arentsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.C. Arentsen more than expected).

Fields of papers citing papers by H.C. Arentsen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.C. Arentsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.C. Arentsen. The network helps show where H.C. Arentsen may publish in the future.

Co-authors

The 25 scholars most cited alongside H.C. Arentsen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H.C. Arentsen Line = papers co-authored together H.C. Arentsen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non–Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations
European Urology ·J. Alfred Witjes, Juan Palou Redorta, Didier Jacqmin, Frank Sofras, Per‐Uno Malmström, Claus Riedl, D. Jocham, Giario Conti, Francesco Montorsi, H.C. Arentsen, Dirk Zaak, Hugh Mostafid, Marko Babjuk
201099
2
Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer
The Journal of Urology ·J. Falke, Rianne J.M. Lammers, H.C. Arentsen, M. Ravic, Raffaella Pozzi, Erik B. Cornel, H. Vergunst, Theo M. de Reijke, J. Alfred Witjes
201234
3
Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer
The Journal of Urology ·Kees Hendricksen, Erik B. Cornel, Theo M. de Reijke, H.C. Arentsen, Santa Chawla, J. Alfred Witjes
201229
4
Experimental rat bladder urothelial cell carcinoma models
World Journal of Urology ·H.C. Arentsen, Kees Hendricksen, Egbert Oosterwijk, J. Alfred Witjes
200920
5
Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model
Therapeutic Advances in Urology ·F. Johannes P. van Valenberg, Dalit Strauss‐Ayali, Yael Agmon-Gerstein, A. Friedman, H.C. Arentsen, H. Ewout Schaafsma, J. Alfred Witjes, Egbert Oosterwijk
201816
6
Fluorescencein situhybridization: a multitarget approach in diagnosis and management of urothelial cancer
Expert Review of Molecular Diagnostics ·H.C. Arentsen, Jean de la Rosette, Theo M. de Reijke, S. Langbein
200613
7
Antitumor Effects of cis -Urocanic Acid on Experimental Urothelial Cell Carcinoma of the Bladder
The Journal of Urology ·H.C. Arentsen, Cornelius F.J. Jansen, Christina A. Hulsbergen‐van de Kaa, Jarmo K. Laihia, Liisa Pylkkänen, Lasse Leino, Egbert Oosterwijk, J. Alfred Witjes
201211
8
LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy
Annals of Oncology ·A. Necchi, Joseph M Jacob, Siamak Daneshmand, Giuseppe Simone, E. Xylinas, David Morris, P. Spiegelhalder, Daniel Zainfeld, Taek Won Kang, Justin T. Matulay, Laurence Belkoff, K. Decaestecker, H.C. Arentsen, S. Hampras, Christopher J. Cutie, Hussein Sweiti, K. Stromberg, J. Martín, Anil Shukla, Michiel S. van der Heijden
202310
9
Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia
World Journal of Urology ·Tom J.H. Arends, J. Falke, Rianne J.M. Lammers, Diederik M. Somford, Jan C.M. Hendriks, Mirjam C.A. de Weijert, H.C. Arentsen, Antoine G. van der Heijden, Egbert Oosterwijk, J. Alfred Witjes
201410
10
The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: An in vitro study
Urologic Oncology Seminars and Original Investigations ·H.C. Arentsen, J. Falke, Anders Høgset, Egbert Oosterwijk, J. Alfred Witjes
20139
11
Management of Low-risk and Intermediate-risk Non–Muscle-invasive Bladder Carcinoma
Hematology/Oncology Clinics of North America ·Yme Weijers, H.C. Arentsen, Tom J.H. Arends, J. Alfred Witjes
20158
12
Pharmacokinetics and toxicity of intravesical TMX‐101: a preclinical study in pigs
British Journal of Urology ·H.C. Arentsen, Christina A. Hulsbergen‐van de Kaa, Cornelius F.J. Jansen, Roberto Maj, Lorenzo M. Leoni, Egbert Oosterwijk, J. Alfred Witjes
20117
13
P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
The Journal of Urology ·Andrea Necchi, Siamak Daneshmand, Giuseppe Simone, Évanguelos Xylinas, David S. Morris, Daniel Zainfeld, Taek Won Kang, Justin T. Matulay, Laurence Belkoff, Karel Decaestecker, H.C. Arentsen, Shalaka Hampras, Christopher J. Cutie, Hussein Sweiti, Katharine Stromberg, Jason Martin, Abhijit Shukla, Michiel S. van der Heijden, Philipp Spiegelhalder, Joseph M Jacob
20247
14
LBA02-03 FIRST RESULTS FROM SunRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE
The Journal of Urology ·Siamak Daneshmand, Michiel S. van der Heijden, Joseph M Jacob, Andrea Necchi, Évanguelos Xylinas, D. S. Morris, Philip Spiegelhalder, Daniel Zainfeld, Taek Won Kang, Justin T. Matulay, Laurence Belkoff, Karel Decaestecker, H.C. Arentsen, Shalaka Hampras, Jin Shu, Christopher J. Cutie, Hussein Sweiti, Katherine Stromberg, Jason Martin, Giuseppe Simone
20235
15
The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations
Urologic Oncology Seminars and Original Investigations ·H.C. Arentsen, Kees Hendricksen, Christina A. Hulsbergen‐van de Kaa, Guru Reddy, Egbert Oosterwijk, J. Alfred Witjes
20093
16
LB003 TAR-200 +/- cetrelimab and cetrelimab alone in patients with bacillus Calmette- Guérin–unresponsive high-risk non–muscle-invasive bladder cancer: updated results from SunRISe-1
European Urology Open Science ·Michiel S. van der Heijden, G. Simone, M. Bögemann, E. Xylinas, M. Roumiguié, Félix Guerrero‐Ramos, A. Necchi, Siamak Daneshmand, C. Van Praet, P. Spiegelhalder, K. Decaestecker, H.C. Arentsen, Daniel Zainfeld, S. Hampras, Christopher J. Cutie, Hussein Sweiti, K. Stromberg, Jeffrey W. Martin, Anil Shukla, Joseph M Jacob
20242
17
179 A PRECLINICAL PLACEBO CONTROLLED EFFICACY STUDY WITH R-837 AND TMX-202 IN AN ORTHOTOPIC RAT BLADDER CANCER MODEL
European Urology Supplements ·J. Falke, H.C. Arentsen, De Kaa C.A. Hulsbergen-Van, Roberto Maj, Egbert Oosterwijk, J.A. Witjes
20112
18
LBA85 TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)
Annals of Oncology ·Michiel S. van der Heijden, G. Simone, Martin Boegemann, E. Xylinas, M. Roumiguié, Félix Guerrero‐Ramos, A. Necchi, Siamak Daneshmand, C. Van Praet, P. Spiegelhalder, K. Decaestecker, H.C. Arentsen, Daniel Zainfeld, S. Hampras, Christopher J. Cutie, Hussein Sweiti, K. Stromberg, Jeffrey W. Martin, Anil Shukla, Joseph M Jacob
20241
19
931 ANTITUMOUR EFFECTS OF CIS-UROCANIC ACID, AN INTRAVESICAL PROTODYNAMIC DRUG, IN EXPERIMENTAL UROTHELIAL CELL CARCINOMA OF THE BLADDER
European Urology Supplements ·H.C. Arentsen, J. Falke, Cornelius F.J. Jansen, Christina A. Hulsbergen‐van de Kaa, Jarmo K. Laihia, Liisa Pylkkänen, L. Leino, Egbert Oosterwijk, J.A. Witjes
20101
20
665 Pharmacokinetics and toxicity of R-837 and TMX-202 after intravesical and intravenous administration: A pre-clinical study in naive rats
European Urology Supplements ·J. Falke, H.C. Arentsen, Christina A. Hulsbergen‐van de Kaa, Roberto Maj, Egbert Oosterwijk, J.A. Witjes
20121

About H.C. Arentsen

H.C. Arentsen is a scholar working on Surgery, Biotechnology, Urology, Genetics and Molecular Biology, having authored 25 papers that have together received 290 indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (8 papers), Cancer Research and Treatments (6 papers), Digestive system and related health (5 papers), Urinary Bladder and Prostate Research (4 papers), Epigenetics and DNA Methylation (3 papers), Urinary Tract Infections Management (3 papers) and Esophageal Cancer Research and Treatment (2 papers). The work is most often cited by research in Urology (62 citations), Surgery (215 citations), Immunology (33 citations), Cancer Research (23 citations) and Toxicology (4 citations). H.C. Arentsen has collaborated with scholars based in Netherlands, Belgium and Italy. Frequent co-authors include J. Alfred Witjes, Egbert Oosterwijk, Theo M. de Reijke, Kees Hendricksen, Erik B. Cornel, Dirk Zaak, Didier Jacqmin, Hugh Mostafid, D. Jocham and Giario Conti. Their work appears in journals such as The Journal of Urology, Urologic Oncology Seminars and Original Investigations, Annals of Oncology, World Journal of Urology and Hematology/Oncology Clinics of North America.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ch. BouffiouxBreakdown of academic impact, for papers by Roberto CarandoBreakdown of academic impact, for papers by Wenxi TanBreakdown of academic impact, for papers by BERND POSCHBreakdown of academic impact, for papers by F. Johannes P. van ValenbergBreakdown of academic impact, for papers by Weidong XuBreakdown of academic impact, for papers by J.P. BurguésBreakdown of academic impact, for papers by Xiaofeng YangBreakdown of academic impact, for papers by U.O. NseyoBreakdown of academic impact, for papers by Myron Roberts